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Walter J. Koch, PHD, Alessandro Cannavo, PHDH eart failure (HF) remains one of the leadingcauses of morbidity and mortality world-wide, and outcomes remain poor despite
improvements in therapy (1). In this regard, it has
been shown that not all patients respond favorably
to some of the more effective therapies, such as
b-adrenergic receptor (bAR) antagonists (2). This
response variability is dependent not only on clinical
features, but also on genetic variation (3,4). Impor-
tantly, technology continues to advance to identify
genetic alterations that may inﬂuence disease devel-
opment as well as therapeutic responses. Indeed,
next-generation sequencing (NGS) has advanced the
study of human genome variation and discrimination
of patients that may respond to speciﬁc therapies (5).
This area of pharmacogenomics is powerful and
several interesting candidate single nucleotide poly-
morphisms (SNPs) recently have appeared to alter
the response to treatment for people with HF.
The current study by Perez et al. (6) used GWAS
to identify a new gene variant candidate that is
strongly associated with altering the response to
conventional HF therapy, which could lead to novel
drug treatments because the candidate gene is a
G protein–coupled receptor (GPCR), a member of a
family of proteins that remains the largest drug-
target system (6,7).SEE PAGE 2522This new ﬁnding from Perez et al. (6) in this issue
of the Journal is especially exciting because the GPCR
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the contents of this paper to disclose.previously linked directly to heart function or cardiac
biology. GPCRs have been the focus of previous
studies dealing with the pharmacogenomics of SNPs
and their relatedness to HF therapeutic responses.
The primary GPCR with this relationship was the
b1-adrenergic receptor (b1AR), and a gene variant has
been found to alter responsiveness to b-blocker
therapy in HF patients (8,9). Of note, the Arg389Gly
b1AR variant is common in the general population,
but with racial differences in its frequency, has been
shown to possess greater ejection fraction improve-
ment in patients carrying the Arg allele (9).
In addition to these single pharmacogenomics
studies showing SNP association with HF responses,
GWAS has been used to robustly ﬁnd gene associa-
tions to the disease itself. Of note, in the current
study by Perez et al. (6), the combination between a
customized SNP array and GWAS led to the discovery
of this new HCRTR2 gene variant that appears highly
associated with therapeutic responsiveness in HF.
Speciﬁcally in this study, the investigators analyzed
866 HF patients. Patients who were found to have a
low functional response to therapy presented with a
variation in the regulatory region of the HCRTR2 gene
(6). Patients without this mutation generally respon-
ded to therapy with a $20% improvement in ejection
fraction. The HCRTR2 gene encodes for a GPCR that is
the receptor for the endogenous neuropeptides
Orexin A or B (also known as hypocretins) (10). The
variant found in the nonresponders generally results
in less expression of the hypocretin receptor (6).
Orexins are produced by neurons of the lateral hy-
pothalamic area and are well known for their effects
on eating behaviors and sleep patterns (6,10). Ac-
cordingly, any cardiovascular effects of orexins or the
hypocretin receptor was viewed as indirect due to
changes in eating or sleeping. As an example of this,
the global or neuronal-speciﬁc knockout in mice of
the orexin gene locus resulted in mice with lower
resting blood pressure compared with wild-type
controls (10). Moreover, the administration of orexin
J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5 Koch and Cannavo
D E C E M B E R 8 , 2 0 1 5 : 2 5 3 4 – 5 Altering the Response to HF Therapy
2535peptides have been associated with increases in
circulating catecholamines and increased heart rate
(10). Thus, no direct effect on cardiac function has
been demonstrated. This Perez et al. (6) study adds
signiﬁcant new knowledge to the cardiovascular
impact of this receptor system and orexins because it
appears to be cardioprotective. Low receptor levels
are associated with decreased therapeutic improve-
ment in HF patients (6).
Interestingly, in addition to the association with
this HCRTR2 gene variant to response to HF treat-
ment, Perez et al. (6) found a consistent increase of
total cardiac hypocretin receptor levels in both
ischemic and dilated cardiomyopathy patients
compared with samples in controls. This suggests a
response to disease progression that may be an
adaptive or compensatory response that may be pro-
tective (6). To directly test this hypothesis, the in-
vestigators created a mouse model with disruptive
transcription of the hyocretin receptor (HCRTR2-TD)
and exposed them to HF models. Although the model
used to induce HF is limited in value because it was
based only on massive neurohormonal treatment
(angiotensin II and isoproterenol), the authors were
able to ﬁnd a signiﬁcant difference in the ﬁbroticresponse and diastolic function in the HCRTR2-TD
mice compared with control mice, strongly suggesting
that loss of receptor worsens HF, and normal levels or
increases with injury are protective (6). Importantly,
the most signiﬁcant support for the hypocretin GPCR
system having positive effects on the heart was from
the beneﬁcial effects of orexin feeding to HF mice.
Stimulation of the hypocretin receptor is an inter-
esting target. Downstream effectors should be studied
for mechanistic insights into potential novel car-
dioprotective strategies.
Overall, the study by Perez et al. (6) is powerful
and provides a translational analysis in humans
and mice for the involvement of the HCRTR2 gene
in HF treatment response. These ﬁndings may
have broader implications for the development of a
new treatment that may “eat away” at the epidemic
of HF.
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